Table 1.
Demographics and Clinical and Molecular Characteristics of Patients With ESFT
| Characteristic | All Patients (N = 132) |
Fusion (No. of patients) |
|||||
|---|---|---|---|---|---|---|---|
| No. | % | EWS-FLI1 Type 1 (n = 70) | EWS-FLI1 Type 2 (n = 19) | EWS-FLI1 Other (n = 17) | EWS-ERG (n = 13) | No Fusion Detected (n = 13) | |
| Positive patients, % | 58.8 | 16.0 | 14.3 | 10.9 | |||
| Age at diagnosis, years | |||||||
| Median | 13 | 13 | 14 | 11 | 12 | 11 | |
| Range | 1-25 | 2-25 | 1-17 | 3-19 | 1-19 | 1-19 | |
| Sex | |||||||
| Male | 72 | 54.5 | 36 | 12 | 9 | 7 | 8 |
| Female | 60 | 45.5 | 34 | 7 | 8 | 6 | 5 |
| Region of tumor | |||||||
| Pelvic | 20 | 15.2 | 12 | 2 | 1 | 2 | 3 |
| Nonpelvic | 112 | 84.8 | 58 | 17 | 16 | 11 | 10 |
| Systemic therapy | |||||||
| AEWS0031 | 100 | 75.8 | 56 | 17 | 10 | 8 | 9 |
| INT-0154 | 32 | 24.2 | 14 | 2 | 7 | 5 | 4 |
| Treatment era | |||||||
| 1996-2000 | 31 | 23.1 | 14 | 0 | 7 | 5 | 5 |
| 2001-2005 | 103 | 76.9 | 56 | 19 | 10 | 8 | 10 |
| Site of origin | |||||||
| Bone | 96 | 72.7 | 50 | 12 | 15 | 10 | 9 |
| Soft tissue | 36 | 27.3 | 20 | 7 | 2 | 3 | 4 |
| Follow-up, years | |||||||
| Median | 4.2 | 4.3 | 3.8 | 4.0 | 5.0 | 4.1 | |
| Range | 0.45-10.9 | 1.2-10.9 | 1.6-5.4 | 0.45-9.2 | 1.4-10.3 | 3.2-8.9 | |
Abbreviation: ESFT, Ewing sarcoma family of tumors.